Compounded semaglutide safety 2026: what the FDA actually says

TLDR. The FDA removed semaglutide from the drug shortage list in October 2024 and tirzepatide in late 2024, which weakened the legal basis for 503A compounding of either drug for broad commercial distribution. Agency adverse-event reporting documents dose-error injuries, salt-form substitutions, and sterility failures specific to compounded GLP-1 products. The molecule itself is the same; the manufacturing and distribution chain is not. Patients on compounded should understand the real risk categories (potency variation, salt form, sterility, supply termination) and not the hype categories.

The compounded semaglutide debate has produced more hot takes than clear facts. Two narratives compete: "compounded is unsafe and the FDA banned it," and "compounded is identical to branded and the FDA is in Novo Nordisk's pocket." Both are wrong in their specifics.

This post lays out what the FDA actually said, in the agency's own statements, on the actual dates the statements were issued. Then it works through the four real risk categories patients should understand and the two risk categories that get overhyped.

The shortage resolution and what it changed

Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to produce drugs that are essentially copies of an FDA-approved drug only under specific conditions, one of which is that the FDA-approved drug is on the agency's drug shortage list.

Semaglutide was on the FDA shortage list from March 2022 through October 2024. During that window, 503A pharmacies could legally compound semaglutide products for commercial distribution. Hims, Mochi, Found, Ro, Noom Med, and dozens of smaller telehealth programs built businesses on this foundation.

The FDA resolved the semaglutide shortage on October 2, 2024. The agency's statement: "Now that the shortage is resolved, FDA expects compounders to stop producing copies of the FDA-approved drug." A 60- to 90-day grace period was given to compounders to wind down inventory and patient pipelines.

Tirzepatide followed a parallel timeline. Shortage listed in late 2022, resolved December 19, 2024. Same wind-down language from FDA.

What changed legally: the broad commercial 503A path for both molecules closed. What did not change: 503A pharmacies may still compound either drug when there is a specific medical-necessity reason for the individual patient that the FDA-approved product does not meet (a documented allergy to a label excipient, for example, or a dose form not commercially available). The medical-necessity carve-out is narrow and patient-specific. It is not a license for continued commercial volume.

What the FDA actually said about safety

The FDA's October 2024 statement on compounded GLP-1s contains the agency's clearest summary of the actual safety concerns. The four specific issues:

One: dose errors. FDA documented multiple cases of patient overdose from compounded GLP-1 products, often involving multi-dose vials where the patient draws into an insulin syringe and confuses "units" with "milligrams." A patient instructed to take 0.25 mg may instead draw 25 units, which is a much higher dose. The agency observed that "the units on syringes are not interchangeable with the mg dosing on GLP-1 labels."

Two: salt-form substitutions. The FDA-approved form of semaglutide is a specific molecular entity. The FDA found that some 503A pharmacies were producing semaglutide using sodium or acetate salt forms instead of the approved form. The agency stated: "These salt forms are not approved by FDA and have not been evaluated for safety or efficacy."

Three: potency variation. Independent testing of compounded GLP-1 products has found a wider potency range than the FDA tolerates for branded products. A vial labeled 5 mg/mL may contain 4.2 to 6.1 mg/mL in compounded production. The branded product is held to a much tighter tolerance through Current Good Manufacturing Practices (cGMP) at FDA-inspected facilities.

Four: sterility failures. Injectable products must be sterile. In 2024 and 2025, the FDA shut down at least two major compounding pharmacies after sterility breaches specific to GLP-1 production. The most prominent case involved a pharmacy producing both compounded semaglutide and compounded tirzepatide that had repeated sterility test failures; the FDA closed the facility and the patient pipeline rerouted to other 503A operators.

The agency's overall position from the October 2024 statement: "FDA continues to receive adverse event reports related to compounded GLP-1 drugs. We urge patients and prescribers to consider the risks of compounded products compared to the FDA-approved products."

What the FDA did not say

Three things the FDA has not stated, which patients sometimes assume:

The FDA did not say compounded GLP-1s are unsafe. The agency said the safety profile is less well-characterized than branded products because compounded products are not produced under the same manufacturing oversight. The risks are real but documented at a population rate of adverse-event reports per patient-month, not a sweeping safety claim.

The FDA did not ban compounding. The shortage resolution closed the broad commercial path. Compounding under medical necessity exceptions remains legal. The FDA cannot ban 503A compounding without an act of Congress.

The FDA did not endorse manufacturer litigation. Novo Nordisk and Eli Lilly have filed lawsuits against compounding pharmacies. The FDA has issued separate warning letters and shutdown orders. The two enforcement paths are parallel, not coordinated, and the FDA does not treat manufacturer litigation as an enforcement substitute.

503A vs 503B: the regulatory distinction

Two categories of compounding pharmacies exist under federal law:

503A pharmacies compound medications one prescription at a time for individual patients. Roughly 7,500 in the United States. State boards of pharmacy regulate them. The FDA inspects 503A pharmacies infrequently, usually only in response to a specific complaint. Compounded semaglutide produced before October 2024 was overwhelmingly 503A product.

503B outsourcing facilities compound medications in larger batches without patient-specific prescriptions, then ship to hospitals and clinics. Roughly 75 registered with the FDA. They are subject to FDA inspection under modified cGMP requirements. 503B facilities can compound shortage-listed drugs without patient-specific prescriptions; once a drug leaves the shortage list, 503B compounding of essentially identical copies is generally prohibited.

For semaglutide and tirzepatide, the 503A path was the dominant source. A few 503B facilities entered the market briefly during the shortage but pulled back after the shortage resolution. Patients receiving compounded GLP-1 in 2026 are almost certainly receiving 503A product.

The regulatory implications matter for risk assessment. 503A oversight is light. The patient is relying on the pharmacy's internal quality controls and the state board's licensing process, not on FDA inspection regimes. Pharmacies with strong internal controls produce safe product; pharmacies without them have produced the dose errors, salt-form substitutions, and sterility failures documented in adverse-event reports.

The real risk categories

Four risks patients on compounded should understand:

Potency variation. A vial labeled at one strength may contain something different. The clinical consequence: a patient titrating up may experience inconsistent effects, GI side effects out of proportion to the labeled dose, or under-dosing that fails to produce expected weight loss. Defense: choose programs that disclose batch testing.

Salt form and excipient variation. The branded products use a specific molecular form and a specific excipient set. Compounded products may use different forms. The clinical consequence is unclear; the regulatory consequence is that the compounded product is not the same drug the trials studied. Defense: ask the program which salt form their pharmacy uses.

Sterility. Sterility failures cause injection-site infections, abscesses, and in rare cases systemic bacterial infections. The clinical consequence ranges from inconvenient (a sore injection site) to serious (sepsis requiring hospitalization). Defense: choose programs that disclose their pharmacy partner and the pharmacy's recent enforcement history.

Supply termination. A 503A pharmacy can be shut down by FDA enforcement, state board action, or commercial failure. The patient's medication pipeline ends with little warning. Defense: have a transition plan to NovoCare or branded coverage; keep 30 days of buffer supply in the refrigerator when possible.

The overhyped risk categories

Two risks that get a lot of attention but matter less than they sound:

"The molecule is different." When 503A pharmacies use the approved semaglutide form (sodium-free, the same form as the branded product), the molecule is the chemical equivalent of branded. Patients sometimes assume compounded semaglutide is a "knockoff" in the sense of being a different drug. It is not. It is the same molecule from a different production chain.

"Compounded is illegal." 503A compounding of GLP-1 medications under medical-necessity exceptions remains legal. The broad commercial path closed after the shortage resolution. Patients on compounded are not engaged in illegal drug use; they are receiving a legally compounded medication under a specific 503A carve-out. Whether the program prescribing it is operating within the carve-out is a separate question.

The Hims-Novo settlement and what it means

On March 9, 2026, Hims & Hers announced a settlement with Novo Nordisk that ended Hims's compounded semaglutide business for new patients and established Hims as an authorized branded Wegovy distributor. The settlement terms were not fully disclosed, but the structural outcome: Hims's compounded patients route to branded Wegovy through Hims's new partnership, with the program covering some portion of the transition cost.

The Hims settlement was the bellwether. Several other programs (Ro, Calibrate, WeightWatchers Clinic) had already exited compounded semaglutide before the settlement. Mochi, Found, and Noom Med continue to dispense compounded as of May 2026, but with documented regulatory exposure.

Patients on compounded with Mochi, Found, or Noom Med in mid-2026 should treat the supply as time-limited. The settlement template Novo Nordisk used with Hims is likely to repeat. Eli Lilly has filed parallel litigation against tirzepatide compounders.

When compounded is appropriate, when it is not

The honest patient cases:

Compounded is reasonable when:

• The patient has tried branded and could not tolerate a specific excipient.
• The patient needs a dose form (low microdose, custom titration) that the branded products do not provide.
• The patient is in a documented commercial-coverage gap with no path to branded affordability.
• The pharmacy partner has clean enforcement history, discloses batch testing, and uses approved salt forms.

Compounded is not appropriate when:

• The patient has a path to branded at NovoCare ($349 to $499) or LillyDirect ($349 to $499) and is choosing compounded purely for price.
• The program does not disclose the pharmacy partner.
• The pharmacy has prior FDA warning letters or recent enforcement actions.
• The patient has no transition plan if compounded supply ends.

The brutal honesty

The compounded GLP-1 era was an artifact of the 2022 to 2024 shortage. Most patients who used it during that window got safe, effective medication at a quarter the price of branded. Some did not. The adverse-event reports the FDA cites are real.

In 2026, the cost gap between compounded ($99 to $199) and branded ($349 to $499) is roughly half what it was in 2023. The regulatory ground is meaningfully weaker. The supply is meaningfully less stable. For most patients in 2026, the right path is branded through NovoCare direct or LillyDirect, not compounded. The exceptions are real but narrower than the volume of compounded prescriptions written in 2024 suggested.

Frequently asked questions

Is compounded semaglutide legal in 2026?

Narrowly, yes, under 503A medical-necessity exceptions for individual patients. Broadly, no, the commercial 503A path closed when the FDA resolved the semaglutide shortage in October 2024. Patients receiving compounded in 2026 are in the medical-necessity space, even if the prescribing program does not frame it that way.

What did the FDA actually say about compounded GLP-1 safety?

In four specific concerns: dose errors from unit-versus-milligram confusion, salt-form substitutions using unapproved sodium or acetate forms, potency variation outside cGMP tolerances, and sterility failures at specific pharmacies. The agency has not stated that compounded GLP-1s are categorically unsafe; it has stated the safety profile is less well-characterized than the branded products.

How do I know if my compounded pharmacy is safe?

Ask the prescribing program three questions: which pharmacy fills your prescription, what is the pharmacy's most recent FDA inspection result, and what salt form of semaglutide does the pharmacy use. Programs that answer these clearly with documented disclosure are operating responsibly. Programs that refuse to identify the pharmacy or that claim "proprietary" production are flags.

Is compounded semaglutide the same as Wegovy?

The molecule is the same when the pharmacy uses the approved form. The manufacturing is different. The clinical effect at the same dose is roughly the same. The risk profile is wider because compounded production is held to lighter oversight than cGMP-produced branded products. See our deeper comparison for the full breakdown.

What happens if my compounding pharmacy gets shut down?

The prescribing program should transition you to branded under insurance or cash-pay. Most programs route to NovoCare direct for cash patients or initiate a prior authorization with the patient's insurance for branded Wegovy or Zepbound. The transition takes 1 to 4 weeks. Build a 30-day medication buffer in advance when possible.

Are there any 503B-compounded GLP-1s still available?

Not in commercial volume. A small number of 503B outsourcing facilities entered the market during the shortage but exited after the resolution because 503B facilities cannot make essentially identical copies of FDA-approved drugs once the shortage is over. Most current compounded GLP-1 supply is 503A patient-specific.

Why is Novo Nordisk suing compounding pharmacies?

The lawsuits assert that 503A pharmacies producing semaglutide outside the medical-necessity carve-outs are infringing on Novo Nordisk's intellectual property and producing unapproved products that compete with the branded drug. The lawsuits do not depend on FDA enforcement; they are independent civil actions. The Hims-Novo settlement in March 2026 is the highest-profile resolution of one of these actions.

Is generic semaglutide the same as compounded?

No. Generic semaglutide will be FDA-approved through the ANDA pathway and produced under cGMP at FDA-inspected facilities, equivalent to the regulatory oversight of branded Wegovy. Generic semaglutide is expected to launch in the United States in late 2026 or early 2027. Once it does, the price gap that motivated compounded will largely close, and most patients should migrate to generic over compounded.

Citations

• FDA. Drug Shortages database, semaglutide resolution announcement, October 2024. accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm
• FDA. Compounding and the FDA: Questions and Answers, 2024 update. fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA. FDA Alerts Health Care Professionals of Dosing Errors Associated with Compounded GLP-1 Injectable Products. May 2024. fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals
• FDA Drug Compounding Advisory Committee. Pharmacy Compounding Advisory Committee meeting materials, October 2023. fda.gov/advisory-committees/pharmacy-compounding-advisory-committee
• 21 U.S.C. § 353a (Section 503A of the Federal Food, Drug, and Cosmetic Act). fda.gov/drugs/human-drug-compounding/section-503a
• FDA Adverse Event Reporting System (FAERS) Public Dashboard. fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee
• National Association of Boards of Pharmacy. 503A and 503B compounding pharmacy regulatory framework summary. nabp.pharmacy/resources